Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Vaccine Production

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

Preclinical Development: Overview

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...

Clinical Trials: Overview

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Microsecond dynamics control the HIV-1 Envelope conformation.

Science advances·2024

Same author

Discovery and Characterization of a Pan-betacoronavirus S2-binding antibody.

bioRxiv : the preprint server for biology·2024

Same author

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.

bioRxiv : the preprint server for biology·2024

Same author

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

Cell·2024

Same author

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.

bioRxiv : the preprint server for biology·2024

Same author

Engineered immunogens to elicit antibodies against conserved coronavirus epitopes.

Nature communications·2023

Search research articles

Related Experiment Video

Updated: May 10, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Progress in HIV-1 vaccine development.

Barton F Haynes¹, M Juliana McElrath

¹Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA. hayne002@mc.duke.edu

Current Opinion in HIV and AIDS

|June 8, 2013

Summary

This summary is machine-generated.

Recent advances in human immunodeficiency virus type 1 (HIV-1) vaccine research show promise. New strategies and rigorous testing are essential for developing an effective HIV-1 vaccine.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Related Experiment Videos

Last Updated: May 10, 2026

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay

Published on: September 14, 2014

Area of Science:

Immunology
Vaccinology
Virology

Background:

The development of an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a critical global health challenge.
Understanding immune responses and viral evolution is key to designing successful interventions.

Purpose of the Study:

To review recent advancements in HIV-1 vaccine research.
To highlight new insights and promising strategies for vaccine development.

Main Methods:

Analysis of immune correlates from the RV144 efficacy trial.
Exploration of novel vaccine vector approaches.
Investigation of broadly neutralizing antibodies (BnAbs) and their development.

Main Results:

RV144 trial insights have accelerated vaccine design and nonhuman primate studies.
New vaccine vectors show potential for controlling acute infection and enhancing T-cell responses.
Elucidation of new broadly neutralizing antibody targets and understanding of their in-host development.

Conclusions:

Developing a successful HIV-1 vaccine necessitates innovative approaches.
Iterative testing of immunogens in well-designed animal and human trials is crucial.